Figure D in S1 file. BEZ235-resistant RCC4 cells do not show altered expression of eIF4E or 4E-BP1 phosphatases, and respond similarly to RAPTOR depletion and rapamycin.
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S1 File contains:
Table A in S1 file: Antibodies used for western blotting and immunoprecipitation Table B in S1 file: Sequences of primers used for qPCR Graphs show relative viability expressed as mean ± SEM of two independent experiments, each with triplicate data points. b. RCC4S and RCC4B20 cells were transfected with control siRNA or MET siRNA, 48 hours later treated with BEZ235, and after a further 72 hr viability was assayed. Graphs: mean and SEM of 6 data points from two independent experiments. MET inhibition or depletion did not influence the response of RCC4S or RCC4B20 cells to BEZ235 (p>0.05 by two-way ANOVA). c-f. RCC4S (left) and RCC4B20 (right) were treated with BEZ235 alone or with c, 10 µM imatinib; d, 10 µM AZD6244; e, 3 µM OSI-906; f, 100 nM DBZ. None of these agents enhanced the response of RCC4B20 cells to BEZ235; indeed imatinib appeared to induce minor increase in resistance (*p,0.05, **p<0.01).
Figure D in S1 file. BEZ235-resistant RCC4 cells do not show altered expression of eIF4E or 4E-BP1 phosphatases, and respond similarly to RAPTOR depletion and rapamycin. a. Cells were treated as Figure B panel a) in S1 File and lysates were western blotted for total eIF4E and 4E-BP1. b. Cells were treated as a) and western blotted for 4E-BP1 phosphatases PP2A C and PPM1G. c. Cells were: left, transfected with control siRNA (siC) or siRAPTOR (siR); right, treated with solvent control or 1 nM rapamycin. All wells were treated 48hr later with solvent in the absence of BEZ235, and viability was assayed 72hr later. Data are expressed as % viability of the appropriate control (*p,0.05, **p<0.01, ***p<0.001).
